Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB)

Raymond James Financial Inc. purchased a new stake in shares of PDS Biotechnology Co. (NASDAQ:PDSB) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 15,865 shares of the company’s stock, valued at approximately $26,000.

Separately, XTX Topco Ltd grew its stake in shares of PDS Biotechnology by 241.8% in the 3rd quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after buying an additional 47,528 shares in the last quarter. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Price Performance

PDSB opened at $1.03 on Monday. The firm has a market capitalization of $46.76 million, a PE ratio of -0.89 and a beta of 1.50. The business’s 50-day moving average is $1.27 and its two-hundred day moving average is $1.98. PDS Biotechnology Co. has a 1 year low of $0.85 and a 1 year high of $4.42. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. Research analysts anticipate that PDS Biotechnology Co. will post -1.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price target on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, PDS Biotechnology has an average rating of “Moderate Buy” and an average price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.